Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

By Steve Cummings, D. Karpf, F. Harris, H. Genant, K. Ensrud, A. LaCroix, D. Black. American Journal of Medicine, 2002

746 citations recorded by the source corpus.

Subfields: Nephrology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/4774ead14c55b0638a89bd8359ece2a67d01aae9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Orthopedics and Sports Medicine

Citations in the corpus

Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. (2008, background): “maceutical treatment, DXA BMDa changes often do not correlate closely with changes in fracture risk (10,11,95,96).”
European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “Whereas 16% of vertebral fracture risk reduction after treatment with alendronate was attributed to an increase in BMD at the lumbar spine [339], larger increases in BMD at both the spine and hip, observed with alendronate, were associated with greater reductions in the risk of non-vertebral fractur”
From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. (2010, background): “Second, only a small part of the reduction in fracture incidence in response to anticatabolic therapy can be accounted for by the increase in bone mass (29).”
European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008, background): “Whereas 16 % of vertebral fracture risk reduction after treatment with alendronate was attributed to an increase in BMD at the lumbar spine [261], larger increases in BMD at both the spine and hip, observed with alendronate, were associated with greater reductions in the risk of nonvertebral fractur”
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards (2011, background): “For example, the change in spine BMD over 3 years explained only 11% of the reduction in spine fracture risk with alendronate [119], 18% for risedronate [120] and close to zero for raloxifene [121].”